| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S84312-1mg |
99.0% | ￥142.00 | 9 | - | - | - |
|
S84312-5mg |
99.0% | ￥489.00 | 6 | - | - | - |
|
S84312-10mg |
99.0% | ￥720.00 | 6 | - | - | - |
|
S84312-25mg |
99.0% | ￥1190.00 | 4 | - | - | - |
|
S84312-50mg |
≥99% | ￥2040.00 | 貨期：2-3天 | - | - | - |
|
S84312-100mg |
≥99% | ￥3570.00 | 貨期：2-3天 | - | - | - |
|
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs).
| 產(chǎn)品描述： | MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs). | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | Auristatin;MicrotubuleAssociated | ||||||||||||||||||||
| 體內(nèi)研究： | The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9. | ||||||||||||||||||||
| 溶解性： | DMSO : 24.5 mg/mL (31.77 mM; Need ultrasonic and warming) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京